Levinson, Nicholas Mark
- University of Minnesota · Pharmacology (NIH department code)
From the FY2023 NIH awards this investigator leads as contact PI. The department is the award's.
FY2023 NIH rank #11,369
- R01 Holder
- Long-Funded
Researcher identity and coverage
- Current affiliation
- Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
- NIH RePORTER identity
- Profile ID unavailableSearch this ID in NIH RePORTER
- ORCID iD
- No ORCID iD on recordA researcher can add one by claiming this profile.
- ScienceDex PI coverage
- FY2009 through FY2023Career claims are limited to the years shown.Metrics use this researcher's latest loaded PI award year; ScienceDex is current through FY2026.
FY2023 award categories
- Pharmacology
NIH Funding · FY2023
Linked Award Amount
$919.2K
Full award amounts, FY2023
Award Records
2
Records listing this PI
Award-Linked Rank
#11,369
By linked amount among FY2023 PIs
Earliest Year Loaded
2009
ScienceDex PI coverage
Award-linked funding history
Linked NIH award amounts and rank by fiscal year.
FY2023 award records by amount
NIH award records listing Levinson, Nicholas Mark as a PI. Multi-PI records show the full award amount for context.
- 5R01CA255513-03R01Contact PIA transformative drug discovery platform for allosteric kinase inhibitorsUniversity of Minnesota · Pharmacology (NIH department code)$571.7Kaward amount
- 5R01CA244645-03R01Contact PITargeting allosteric scaffolding functions of Aurora kinase A in cancerUniversity of Minnesota · Pharmacology (NIH department code)$347.5Kaward amount
Award organization
Organizations that administered FY2023 awards listing Levinson, Nicholas Mark as a PI.
FY2023 award administered by University of Minnesota (MN).
Coverage and award-record milestones
Computed from the fiscal years currently available in ScienceDex.
- 2009First NIH AwardUniversity of Minnesota
- 2013R01 Grant Holder
- 2015$500K Cumulative Funding
- 2017$1M Cumulative Funding
- 2019$2M Cumulative Funding
- 2020Entered Top 50% NationallyRanked #6153
- 2021Entered Top 25% NationallyRanked #4632
- 2022$5M Cumulative Funding